Clinico-pathological  	Clinico-pathological  	 NNP	B-NP
and  	and  	 CC	O
molecular  	molecular  	 JJ	B-NP
subtypes  	subtypes  	 NN	I-NP
of  	of  	 IN	O
male  	male  	 JJ	O
breast  	breast  	 NN	O
carcinoma  	carcinoma  	 VBZ	O
according  	according  	 VBG	O
to  	to  	 TO	O
immunohistochemistry  	immunohistochemistry  	 VB	O
Male  	Male  	 JJ	B-NP
breast  	breast  	 NN	I-NP
carcinoma  	carcinoma  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
rare  	rare  	 JJ	O
condition 	condition 	 NN	O
,  	,  	 ,	O
but  	but  	 CC	O
with  	with  	 IN	O
a  	a  	 DT	O
trend  	trend  	 NN	O
of  	of  	 IN	O
increase  	increase  	 NN	B-NP
frequency 	frequency 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
our  	our  	 PRP$	O
study 	study 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
investigate  	investigate  	 VB	O
the  	the  	 DT	O
clinico-pathological  	clinico-pathological  	 JJ	B-NP
features  	features  	 NNS	I-NP
and  	and  	 CC	O
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
at  	at  	 IN	O
35  	35  	 CD	O
male  	male  	 JJ	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
primary  	primary  	 JJ	B-NP
invasive  	invasive  	 JJ	I-NP
breast  	breast  	 NN	I-NP
carcinoma  	carcinoma  	 NN	I-NP
correlated  	correlated  	 NN	I-NP
with  	with  	 IN	O
molecular  	molecular  	 JJ	B-NP
subtypes  	subtypes  	 NNS	I-NP
defined  	defined  	 VBN	O
by  	by  	 IN	O
immunohistochemical  	immunohistochemical  	 JJ	B-NP
profile 	profile 	 NN	I-NP
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
immunohistochemical  	immunohistochemical  	 JJ	B-NP
expression  	expression  	 NN	I-NP
profiles  	profiles  	 NNS	I-NP
of  	of  	 IN	I-NP
estrogen  	estrogen  	 JJ	I-NP
receptor  	receptor  	 NN	I-NP
( 	( 	 -LRB-	O
ER 	ER 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
progesterone  	progesterone  	 JJ	B-NP
receptor  	receptor  	 NN	I-NP
( 	( 	 -LRB-	O
PR 	PR 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
human  	human  	 JJ	B-NP
epidermal  	epidermal  	 JJ	I-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
2  	2  	 CD	I-NP
( 	( 	 -LRB-	O
HER2 	HER2 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
Ki67 	Ki67 	 NNP	B-NP
,  	,  	 ,	O
EGFR  	EGFR  	 NNP	B-NP
and  	and  	 CC	O
CK5 	CK5 	 CD	B-NP
/ 	/ 	 CD	O
6 	6 	 CD	O
,  	,  	 ,	O
the  	the  	 DT	O
male  	male  	 JJ	O
breast  	breast  	 NN	O
cancers  	cancers  	 NNS	O
were  	were  	 VBD	O
classified  	classified  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
following  	following  	 JJ	O
molecular  	molecular  	 JJ	B-NP
subtypes 	subtypes 	 NN	I-NP
:  	:  	 :	O
Luminal  	Luminal  	 NNP	B-NP
A 	A 	 NNP	O
,  	,  	 ,	O
Luminal  	Luminal  	 NNP	B-NP
B 	B 	 NNP	I-NP
,  	,  	 ,	O
HER2+ 	HER2+ 	 NNP	B-NP
,  	,  	 ,	O
triple  	triple  	 RB	O
negative  	negative  	 JJ	O
and  	and  	 CC	O
unclassified 	unclassified 	 JJ	O
.  	.  	 .	O
In  	In  	 IN	O
our  	our  	 PRP$	O
study 	study 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
identified  	identified  	 VBD	O
65.7 	65.7 	 CD	O
%  	%  	 NN	O
as  	as  	 IN	O
Luminal  	Luminal  	 NNP	B-NP
A  	A  	 DT	O
subtype  	subtype  	 NN	B-NP
and  	and  	 CC	O
28.6 	28.6 	 CD	O
%  	%  	 NN	O
as  	as  	 IN	O
Luminal  	Luminal  	 NNP	B-NP
B  	B  	 NNP	I-NP
subtype 	subtype 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
difference  	difference  	 NN	O
was  	was  	 VBD	O
represented  	represented  	 VBN	O
by  	by  	 IN	O
two  	two  	 CD	O
( 	( 	 -LRB-	O
5.7 	5.7 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
triple  	triple  	 JJ	O
negative  	negative  	 JJ	B-NP
subtype 	subtype 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
due  	due  	 JJ	O
to  	to  	 TO	O
low  	low  	 JJ	O
number  	number  	 NN	O
of  	of  	 IN	O
patients 	patients 	 NNS	O
,  	,  	 ,	O
no  	no  	 DT	O
correlations  	correlations  	 NN	B-NP
or  	or  	 CC	O
prognostic  	prognostic  	 JJ	B-NP
significance  	significance  	 NN	I-NP
could  	could  	 MD	O
be  	be  	 VB	O
assessed  	assessed  	 VBN	O
in  	in  	 IN	O
these  	these  	 DT	O
cases 	cases 	 NNS	O
.  	.  	 .	O
No  	No  	 DT	O
HER2  	HER2  	 NNP	B-NP
or  	or  	 CC	O
unclassified  	unclassified  	 JJ	O
subtypes  	subtypes  	 NN	B-NP
were  	were  	 VBD	O
identified 	identified 	 VBN	O
.  	.  	 .	O
Luminal  	Luminal  	 VBG	O
A  	A  	 DT	O
tumors  	tumors  	 NNS	O
are  	are  	 VBP	O
the  	the  	 DT	O
most  	most  	 RBS	O
frequent  	frequent  	 JJ	O
subtype  	subtype  	 NN	B-NP
in  	in  	 IN	O
MBC 	MBC 	 NNP	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
better  	better  	 JJR	O
outcome  	outcome  	 NN	O
than  	than  	 IN	O
Luminal  	Luminal  	 NNP	B-NP
B  	B  	 NNP	I-NP
subtype 	subtype 	 NN	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
recorded  	recorded  	 VBD	O
high  	high  	 JJ	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
ER  	ER  	 NNP	B-NP
and  	and  	 CC	O
PR  	PR  	 NNP	B-NP
expression 	expression 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
predict  	predict  	 VBP	O
a  	a  	 DT	O
better  	better  	 JJR	O
response  	response  	 NN	O
to  	to  	 TO	O
adjuvant  	adjuvant  	 VB	O
hormonal  	hormonal  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
At  	At  	 IN	O
the  	the  	 DT	O
time  	time  	 NN	O
of  	of  	 IN	O
diagnosis 	diagnosis 	 NN	O
,  	,  	 ,	O
most  	most  	 JJS	O
of  	of  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
aged  	aged  	 VBN	O
and  	and  	 CC	O
with  	with  	 IN	O
an  	an  	 DT	O
advance  	advance  	 NN	O
clinical  	clinical  	 JJ	B-NP
stage 	stage 	 NN	I-NP
,  	,  	 ,	O
this  	this  	 DT	O
requiring  	requiring  	 VBG	B-NP
implementation  	implementation  	 NN	I-NP
of  	of  	 IN	I-NP
screening  	screening  	 VBG	I-NP
programs  	programs  	 NNS	I-NP
and  	and  	 CC	O
increase  	increase  	 NN	B-NP
education  	education  	 NN	I-NP
of  	of  	 IN	O
population  	population  	 NN	O
in  	in  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
an  	an  	 DT	O
early  	early  	 JJ	O
detection 	detection 	 NN	O
.  	.  	 .	O
